Podcasts about CMC

Covino & Rich broadcast live from Radio Row in San Francisco for Super Bowl 60 in this Best Of edition! The guys are joined by the Panthers QB Bryce Young & Running Back Rico Dowdle to talk all things about locker room dynamics & how the team will be back better than ever next year. 49ers Wide Receiver Kendrick Bourne joins the guys to talk about their one of a kind of comradery in the locker room, how CMC has been such a huge part of that strong team foundation + Comedian Frank Caliendo stops by! See omnystudio.com/listener for privacy information.

49ers Wide Receiver Kendrick Bourne joins the guys to talk about the team's one of a kind of comradery in the locker room, how CMC has been such a huge part of that strong team foundation & if he believes there’s some kind of truth behind those practice field conspiracies in San Fran! Comedian Frank Caliendo swings by & goes over the impressions the guys always do on a regular basis! See omnystudio.com/listener for privacy information.

Following Robert Saleh's hiring as Tennessee Titans head coach, sources confirmed to NBC Sports Bay Area that Raheem Morris will sign on as San Francisco's fifth defensive coordinator in the last five seasons. Also, in another top organizational move, Jed York announced Monday the promotion of Al Guido to the role of CEO. On this episode of "49ers Talk," Matt Maiocco sits down with Guido to discuss his promotion, his hard work in bringing Super Bowl LX to the Bay Area and how the 49ers' front office and coaching staff's synergy has provided stability that is rare in the NFL these days. They also touch upon the logistics required to host a Super Bowl twice in 10 years, and the possibility of the 49ers playing two international games this coming season. Matt also interviews talkSPORT commentator Will Gavin about his viral call of the "Skyy Bang Reverse Pass" play that was key to San Francisco's fourth-quarter comeback vs. the Eagles in NFC wild-card playoffs.--6:00 - 1-on-1 with newly promoted 49ers CEO Al Guido12:00 Guido's work on bringing Super Bowl LX to Levi's14:00 - Dynamic between the coaching staff and 49ers' front office19:00 - 49ers are in a window next season to play international home game or two20:00 - talkSPORT commentator Will Gavin breaks down viral call of 49ers play23:00 - More people have contacted CMC about the call than the actual play  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.

The cultivated meat industry has captured headlines and struggled with economics. Meanwhile, plant cell biomanufacturing is quietly solving the cost equation and approaching commercial launch. The question isn't whether cellular agriculture can work at scale. It's which applications will get there first, and what bioprocessing innovations will make it possible.In Part 2, we dive into the commercialization challenges that separate laboratory curiosity from market-ready products. Steven Lang tackles the hard questions: How do you replicate chocolate's complex flavor profile without traditional fermentation? What analytical infrastructure ensures product consistency and safety? And how do you build the right team and data foundation to navigate the journey from premium launch to commodity-scale production?Steven's background spanning Johnson & Johnson, Genentech, and Upside Foods gives him a unique perspective on what works and what doesn't when translating biopharma rigor to food applications. At California Cultured, he's applying those lessons to launch high-flavanol cocoa powder in 2026, with a clear roadmap to commodity cocoa and coffee thereafter.In this episode:The challenge of replicating chocolate's taste and fermentation in the lab (02:39)How plant cell culture differs from conventional farming and its advantages for safety and scalability (03:03)Analytical methods and equipment needed for consistent, safe, and high-quality cultured cocoa products (05:05)The potential for cell-based food to minimize heavy metals and other contaminants in chocolate (06:09)Environmental implications: tackling climate change, deforestation, and the realistic timeline for widespread adoption of lab-grown foods (06:50)Emerging opportunities beyond cocoa and coffee—saffron, ginseng, echinacea, and even lab-grown wood (08:40)Key advice for scientists and entrepreneurs interested in entering the cellular agriculture field (10:12)Building successful teams and robust data foundations in biotech startups (11:43)Key takeaway:Cellular agriculture's future isn't a single technology replacing conventional food production. It's multiple parallel approaches creating resilience in global food systems. The opportunity is clear: the technical principles you've mastered in biopharma translate directly to food applications, but the faster commercialization timelines and novel business models require rethinking what "stage-appropriate development" means.The question for bioprocess leaders is whether you'll help build the solutions to bridge the food production gap, or watch from the sidelines as food security becomes the defining challenge of our generation.Here is the previous conversation with Steven Lang:Episodes 55-56: Cultivated Meat: A Promising Future or an Inevitable Bubble? with Steven LangConnect with Steven Lang:LinkedIn: www.linkedin.com/in/steven-lang-b003406California Cultured Inc.: www.cacultured.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

On today's show Andrew and Bill react to the news that the rumors were true, and CMC members Zhang Youxia and Liu Zhenli are under investigation for corruption. Topics include: The timing of the announcement from the Defense Ministry, why this weekend's news inspired such a volume of reactions around the world, a history of Xi's crackdowns on the PLA, questions about rumors of a coup against Xi, reports that Zhang Youxia was working with the U.S., the PLA corruption heyday and its implications for what might come next, and various ways to think about the implications for Taiwan. At the end: The first batch of H-200s is approved for purchase, and the TikTok sale is approved as users lash out with censorship claims.

Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.

In this episode of Inside Winemaking, Jim Duane speaks with Leigh Meyering of MyEnologist about the practical and analytical aspects of heat and cold stability in wine. The discussion focuses on how and why protein haze and tartrate instability occur, with an emphasis on white and rosé wines. Leigh explains the principles behind heat stability testing, protein denaturation, and the use of bentonite to prevent haze, as well as how stability concerns differ between red wines and lighter-colored styles. The conversation also addresses the sensory and chemical impacts of stabilization decisions, including common concerns around stripping, mouthfeel, and visual clarity in finished wines. The episode then moves into cold stability, detailing the Davis conductivity, DIT, and ISTC 50 tests and how to choose the appropriate method based on a winery's stabilization strategy. Leigh outlines the roles of traditional chilling and seeding, carboxymethyl cellulose (CMC), and mannoproteins, including their limitations and compatibility with protein stability. Throughout the discussion, Jim and Leigh emphasize correct sampling strategy, filtration level selection, and timing of tests to ensure results accurately represent the wine that will be bottled. Practical lab workflows, sample volume requirements, and real-world bottling considerations are covered to help winemakers reduce risk and avoid post-bottling stability issues. Leigh previously appeared on Inside Winemaking in May 2019 to discuss the founding and early development of her wine lab, MyEnologist, including its analytical services and role in supporting winemakers. This episode builds on that earlier conversation by applying lab-based analysis directly to cellar decision-making, with a focused, technical look at stability testing and intervention strategies used in modern winemaking.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he's now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of keeping development, financing, and hiring in sync as biotech companies grow, his experiences surviving near-death cash deficits, the importance of investing early in CMC, and what to expect in 2026.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

2026-01-26 | UPDATES #113 | “Treason” in the PLA? Xi's unprecedented purge — corruption, loyalty, and coup rumours. Today's story is not “just another corruption scandal” in China. This is the Chinese Communist Party reaching up into the absolute top of the People's Liberation Army — right into the room where war plans live — and yanking out two senior figures in one move. Top figures in fact. Beijing's official language is clipped. The implications are not. China's defence ministry says it has opened investigations into General Zhang Youxia — a vice chairman of the Central Military Commission, effectively the uniformed number two under Xi Jinping — and General Liu Zhenli, a CMC member and chief of the Joint Staff Department. The stated reason: “suspected serious violations of discipline and law.” (Reuters)----------SUPPORT THE CHANNEL:https://www.buymeacoffee.com/siliconcurtainhttps://www.patreon.com/siliconcurtain----------SOURCES: Xinhua: Defence ministry announcement (Jan 24, 2026). Xinhua / PLA Daily editorial summary (Jan 24, 2026). Reuters: Investigation details and context on PLA purges (Jan 24, 2026). Associated Press: Overview and recent purge timeline (Jan 24, 2026).Financial Times: Loyalty framing and “authority” angle (Jan 25, 2026). Washington Post: Scale of upheaval and command implications (Jan 25, 2026).Wall Street Journal: Reported additional allegations (unconfirmed by PRC statement) South China Morning Post: “Party purity” framing and political timing (Jan 25, 2026). Official explainer of the “CMC Chairperson Responsibility System” (SCIO, background).Reuters (background): Li Shangfu/Wei Fenghe expulsions (Jun 2024) and 2027 readiness reporting (Feb 2023). German Marshall Fund (background): Rocket Force shakeup (Aug 2023). Andrew Erickson (analysis aggregation; includes translated/linked primary text). Sinocism (analysis; discussion of messaging speed and implications). ----------SILICON CURTAIN LIVE EVENTS - FUNDRAISER CAMPAIGN Events in 2025 - Advocacy for a Ukrainian victory with Silicon Curtainhttps://buymeacoffee.com/siliconcurtain/extrasOur events of the first half of the year in Lviv, Kyiv and Odesa were a huge success. Now we need to maintain this momentum, and change the tide towards a Ukrainian victory. The Silicon Curtain Roadshow is an ambitious campaign to run a minimum of 12 events in 2025, and potentially many more. Any support you can provide for the fundraising campaign would be gratefully appreciated. https://buymeacoffee.com/siliconcurtain/extras----------

What happens when we move beyond oversimplified cell cultures and truly embrace the complexity of human biology? In this episode of the Smart Biotech Scientist Podcast, we explore how advanced 3D cell models are reshaping preclinical research—recreating human tissue microenvironments to better understand tumors, immunotherapies, and gene and cell therapies.David's guest is Catarina Brito, Principal Investigator at ITQB NOVA and Head of the Advanced Cell Models Laboratory at iBET and ITQB NOVA (Portugal). Her work bridges academia and industry through iBET, a unique partnering organization that integrates cell engineering, bioprocessing, and translational modeling.Catarina's pioneering models help both pharma leaders and startups predict drug resistance and immunogenicity earlier and more reliably, accelerating the path to safer, more effective therapies—well before clinical trials begin.Topics discussed:Understanding the contribution of stromal and immune cells to therapy outcomes in tumor microenvironments (03:42)Studying immune responses to gene therapy vectors with advanced neural models (04:31)Combining multi-omics and spatial data with AI for predictive biology and patient-specific digital twins (05:16)Catarina's advice: Start simple, let the biological question dictate model design, and avoid premature overengineering (06:53)Importance of reproducibility, process controls, and standardization in advanced models (08:10)How academic-industry collaborations drive model development, scalability, and real-world relevance (08:42)Common pitfalls: Overengineering, poor cell source selection, insufficient system validation (11:03)Next steps for precision medicine and translational research using advanced cell models (13:08)Want to know how leading scientists make advanced cell models actionable and collaborative for pharma breakthroughs? Tune in for practical strategies, real-world collaborations, and pitfalls to avoid as you scale your own translational research.Connect with Catarina Brito:LinkedIn: www.linkedin.com/in/catarina-brito-ibetAdvanced Cell Models Lab – iBET: www.ibet.pt/laboratories/advanced-cell-models-labNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.

What if the failure rate in clinical trials isn't about picking the wrong drug candidates—but about testing them in the wrong models?When you move cells from a 2D culture plate into a bioreactor, you're not simply scaling volume. You're fundamentally changing the biological context. Cell density shifts. Mass transfer dynamics evolve. Mechanical cues emerge. The cells sense these changes and respond—often in ways that derail strategies built on oversimplified assumptions.Most preclinical research still relies on flat plastic surfaces and animal models that miss critical aspects of human biology. The result? Therapeutics fail late in development because the models couldn't predict how human tissues would actually respond.In this episode, David Brühlmann speaks with Catarina Brito, Principal Investigator at ITQB NOVA and Head of the Advanced Cell Models Laboratory at iBET and ITQB NOVA in Portugal. Catarina's career-defining insight came early: studying glycan-protein interactions in murine versus human cells revealed that species differences weren't just nuances—they were fundamental gaps that could mislead entire research programs.Catarina and her team have developed neural, liver, and tumor models that capture the multicellular complexity and microenvironmental cues that 2D cultures cannot replicate. Her work creates preclinical models sophisticated enough to predict human responses while remaining scalable for drug development workflows.Highlights of the episode:Limitations of traditional 2D cell cultures and animal models in capturing realistic tissue behavior and therapeutic responses (06:27)Catarina Brito's personal scientific journey: from discovering model limitations to pioneering 3D culture systems in neural and liver tissues (04:19)How advanced 3D models recreate cell-to-cell interactions, tissue-specific microenvironments, diffusion gradients, and multicellular complexity (10:35)Regulatory movements toward reducing animal models, and the challenge of validating advanced alternatives for systemic biology studies (09:10)Key differences in designing bioreactors for various cell types, with practical examples from liver and neural models (15:16)The impact of scalable, robust 3D models on accelerating drug development and improving selection of candidate therapies (17:22)Key Takeaway:Bioprocess development starts when you choose the model that validates your therapeutic approach. If that model can't capture the biology that matters, every downstream optimization is built on a flawed foundation.In Part 2, Catarina reveals how 3D tumor microenvironments expose drug resistance mechanisms invisible in 2D cultures, and her vision for AI-powered digital twins enabling personalized medicine.Subscribe & Review:If this conversation changed how you think about preclinical model selection, leave a review on Apple Podcasts. Your reviews help other biotech scientists discover these insights.For more CMC development insights, visit smartbiotechscientist.com.Connect with Catarina Brito:LinkedIn: www.linkedin.com/in/catarina-brito-ibetAdvanced Cell Models Lab – iBET: www.ibet.pt/laboratories/advanced-cell-models-labNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Seahawks, Broncos WIN.. Nix ankle; CMC injury

The biotech industry stands on the verge of a radical transformation thanks to artificial intelligence (AI) and machine learning (ML). But even the most sophisticated algorithms are only as smart as the data feeding them.David Brühlmann sits down with Troy Lionberger, Chief Business Officer at A-Alpha Bio, whose team has quietly shattered the data ceiling by measuring and curating more than 1.8 billion protein interactions. Troy Lionberger brings an insider's perspective from the frontlines of machine learning-powered drug discovery. From partnering with leading biotechs to redesigning classic antibodies for previously “impossible” targets, Troy's work pushes the edges of what's tractable in biologic therapeutics.What you'll hear in this episode:Limitations of public data sources like the Protein Data Bank and their impact on current protein engineering approaches (03:11)Why combining energetic (ΔG) and structural data matters for building predictive protein engineering models (05:43)A-Alpha Bio's approach to generating 1.8 billion protein interaction measurements for machine learning—what this enables today and what's possible next (06:30)Examples of how A-Alpha Bio's platform solves challenging therapeutic problems, such as optimizing molecules for 800+ HIV variants and engineering dual-specific antibodies (07:36)The ongoing debate: What capabilities should biotech companies keep in-house, and what works best outsourced to service providers? (09:59)The potential of synthetic epitopes as vital tools for training models beyond the Protein Data Bank—introducing the Synthetic Epitope Atlas (12:09)Key takeaways for scientists: the importance of diligence amidst rapidly evolving AI claims, and advice for accelerating R&D with the right data (14:57)Wondering how to move protein therapeutics from “interesting” to “impactful” without waiting for years of crystal structures? Listen in to learn how you can harness next-gen machine learning tools and custom datasets for your development projects.Connect with Troy Lionberger:LinkedIn: www.linkedin.com/in/troylionbergerA-Alpha Bio website: www.aalphabio.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.

Spadoni and Shasky discuss the Warriors win, Fred Warner's return and the guys play with some hypotheticals to show how desperate 49ers fans are to win the Super Bowl. Plus, who are guys that were traded that felt like they lived their career in one spot, like CMC?

In this edition of What the Bleep, Celtics head coach Joe Mazzulla goes viral for another excellent press conference, a young Eagles fan talks about a tough playoff loss, Jason Garrett had an unfortunate misspeak on CMC, a woman has a food snorting addiction, & more See omnystudio.com/listener for privacy information.

Antibody therapeutics have transformed modern medicine, but for many scientists, developing new candidates still feels like searching for a needle in a haystack—a slow, expensive, and unpredictable process. Structural biology and high-throughput data generation are now collapsing that haystack, offering unprecedented visibility into the molecular handshake that drives life: protein-protein interactions.In this episode, David Brühlmann sits down with Troy Lionberger, Chief Business Officer at A-Alpha Bio, for an in-depth discussion on protein-protein interactions and how advances in data generation and machine learning are transforming antibody discovery and drug development.Troy Lionberger shares his journey into biotechnology, challenges long-held beliefs about antibody development, and explains how Alphabio's high-throughput affinity measurements are shortening timelines and improving outcomes for therapeutic development.In this episode, you'll learn about:The historical and current challenges in characterizing these interactions at scale (06:22)How new technologies—especially high-throughput platforms—are changing the needle-in-the-haystack approach (08:40)A comparison of traditional in vivo and in vitro antibody discovery methods, along with their strengths and limitations (09:06)The evolving role of AI and machine learning in antibody discovery and lead optimization (12:11)Real-world examples of how A-Alpha Bio's approach is compressing years of work into months without sacrificing quality (13:58)The science behind A-Alpha Bio's AlphaSeq technology and how it leverages yeast display and genomics for large-scale affinity measurements (20:43)The practical affinity range the technology can measure, covering most therapeutic applications (23:25)Whether you're a scientist navigating CMC or a biotech professional curious about next-generation workflows, this episode offers practical insights into both traditional and emerging methodologies in the field.Connect with Troy Lionberger:LinkedIn: www.linkedin.com/in/troylionbergerA-Alpha Bio website: www.aalphabio.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show

Hour 1: From underdogs to upset kings! The Niners storm Philly with a 23–19 win behind Brock Purdy’s clutch late TD and a jaw‑dropping trick‑play pass from Jauan Jennings to CMC, and KNBR 49ers insider Larry Krueger joins the show to break it all downSee omnystudio.com/listener for privacy information.

Christian McCaffrey put on a masterclass performance as the San Francisco 49ers went into Philadelphia and handled business against the Philadelphia Eagles.CMC was unstoppable, setting the tone early and taking over the game from start to finish. Physical runs, explosive plays, and straight dominance — this was a statement win on the road.

Hour 1: From underdogs to upset kings! The Niners storm Philly with a 23–19 win behind Brock Purdy’s clutch late TD and a jaw‑dropping trick‑play pass from Jauan Jennings to CMC, and KNBR 49ers insider Larry Krueger joins the show to break it all downSee omnystudio.com/listener for privacy information.

Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.

In hour 2, Spadoni and Shasky discuss what to expect from CMC this weekend in Philly and what the offensive game plan should be for the 49ers.

Every Wednesday in January, Matt Harmon and Justin Boone take a look back at the 2025 fantasy season to find lessons they learned and can apply to the 2026 fantasy season. For today's pod the two look at their biggest takes from last summer to see what they got right and wrong at the QB and RB position. To end the show, Harmon debuts our new 'Dynasty Debates' segment where listeners send in their most pressing dynasty questions this fantasy offseason.(4:50) -Things we got WRONG at QB: Matthew Stafford, Bryce Young, JJ McCarthy(21:45) - Things we got WRONG at RB: Cowboys Backfield, Seahawks Backfield, Saquon Barkley(33:45) - Things we got RIGHT at QB: Drake Maye, Trevor Lawrence, Dak Prescott, Kyler Murray(41:50) - Things we got RIGHT at RB: Ashton Jeanty, CMC, TreVeyon Henderson, Chase Brown, RJ Harvey, Bijan Robinson(51:15) - Dynasty Debates: Matt and Justin answer your questions  Subscribe to the Yahoo Fantasy Forecast on your favorite podcast app:

For generations, silkworm pupae were discarded as waste from silk production. Now, KAICO is proving these organisms can function as highly efficient protein factories—producing complex vaccine antigens at yields and costs that challenge conventional bioreactor-based manufacturing. With a PCV2 oral vaccine already registered in Vietnam and a human norovirus vaccine preparing for Phase I clinical trials, the silkworm platform is moving from proof-of-concept to commercial reality.In Part 2, Masafumi Osawa, Business Development Lead at KAICO, walks us through the company's product pipeline, the regulatory landscape for this unprecedented platform, and why silkworm-based manufacturing could reshape global vaccine accessibility. From farm-scale validation to regulatory dialogue with Japan's PMDA, this episode bridges platform science with product development.Stops along our Silk Road to biomanufacturingKAICO's approach to expressing complex proteins, including oral and injectable vaccines for animals and clinical-stage human health products (00:40)Immune-enhancing feed additive for pigs against PCV2 (registered in Vietnam), companion animal products, and human norovirus vaccine entering Phase 1 trials (02:50)Advantages of silkworm-produced antigens for both injectable and oral vaccines, and comparison to plant-based systems (04:57)How silkworm production enables rapid scale-out and high-yield protein expression for global accessibility (05:34)Speed of vaccine development with the silkworm platform—example with SARS-CoV-2 recombinant protein produced in three months (08:08)Key regulatory differences between animal and human vaccine development, including country-specific classification and global harmonization efforts (09:14)Sustainability and distributed manufacturing potential of silkworm-based systems (11:10)Milestones toward the first human biologic produced in silkworms, with phase 1 trials starting soon (12:27)Protein yield per silkworm pupae—scalability advantages compared to conventional bioreactor approaches (14:04)Masafumi Osawa's thoughts on the future of silkworm-based biologics: from democratized therapies to personalized medicines (15:15)Want to know if silkworms can solve your tough protein expression problems? Tune in now to learn how KAICO's biotech is set to redefine what's possible for vaccine development, and how their distributed, cost-effective approach could open doors across sectors.Connect with Masafumi Osawa,:LinkedIn: www.linkedin.com/in/masa-osawaKAICO Ltd.: www.kaicoltd.jp/enNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.

For over 4,000 years, silkworms have connected civilizations through ancient trade routes. Now, KAICO Ltd., a Japanese biotech spin-off from Kyushu University, is transforming these creatures into living bioreactors capable of producing complex recombinant proteins and vaccine antigens—without the bioreactors, expensive media, or massive water consumption of conventional platforms.Masafumi Osawa, Business Development Lead at KAICO, brings an unconventional path to biotech. Trained in cultural anthropology with fieldwork experience in Indonesia, he witnessed firsthand the healthcare disparities that drive his current mission. After years in pharmaceutical business development at Towa Pharmaceutical, he joined KAICO to help scale a technology he believes could reshape global vaccine accessibility. His cross-cultural expertise now proves invaluable as KAICO expands internationally, with active partnerships in Vietnam and Thailand and growing interest from other regions.Episode highlights:Masafumi's transition from anthropology to biotech, and how cross-cultural expertise benefits global health collaborations. (04:15)The founding story of KAICO, spun out from Kyushu University and focused on recombinant proteins and vaccine antigen production (08:45)Step-by-step overview of the silkworm baculovirus expression system, including pupae handling and bioprocessing basics. (10:28)Practical differences between silkworms, E. coli, mammalian, and insect cell culture platforms—exploring advantages and drawbacks. (13:10)Strategies KAICO uses to control silkworm variability, including SPF grade sourcing, diet, environment, and documentation for pharmaceutical acceptance. (15:08)Production scalability: a single pupa can match 100–1000 ml of insect cell culture, with major implications for cost and environmental footprint. (16:42)Downstream harvesting and purification—how KAICO extracts and processes proteins from silkworm pupae, keeping methods largely familiar to traditional systems. (19:31)Regulatory and GMP challenges of using live organisms, and KAICO's approach to satisfying authorities and ensuring product consistency. (21:43)Whether you're curious about alternative biomanufacturing methods or want a transparent look at silkworm-based protein expression from research to the clinic, this episode delivers practical insights and thoughtful discussion.Connect with Masafumi Osawa:LinkedIn: www.linkedin.com/in/masa-osawaKAICO Ltd.: www.kaicoltd.jp/enNext step:Need fast CMC guidance? → Get rapid CMC decision support hereOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show

Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.

Brian Baldinger joins The Roast to talk about the incredible game from Sunday night, what is impressing about Brock Purdy and CMC, as well as how the Niners can beat the Seahawks on Saturday night

Daniel and Chelsea discuss King Henry and CMC's performances in week 17, how nobody wants to win the NFC South, the Giants blowing the first overall pick and more topics!

Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube, or visit our website CMChurch.com

Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.

Welcome to the Paint The Medical Picture Podcast, created and hosted by Sonal Patel, BA, CPMA, CPC, CMC, ICD-10-CM.Thanks to all of you for making this a Top 15 Medical Billing & Coding Podcast for 5 years on Feedspot.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sonal's 16th Season starts up and Episode 17 features Newsworthy updates on the month's fraud, waste, and abuse cases. Sonal's Trusty Tip and compliance recommendations focus on podiatry practices' evaluation and management services with modifier 25.Spark inspires us all to reflect on resilience based on the inspirational words of Winston Churchill.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Paint The Medical Picture Podcast now on:Spotify:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/show/6hcJAHHrqNLo9UmKtqRP3X⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple Podcasts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/paint-the-medical-picture-podcast/id153044217⁠7⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon Music: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://music.amazon.com/podcasts/bc6146d7-3d30-4b73-ae7f-d77d6046fe6a/paint-the-medical-picture-podcas⁠t⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Find Paint The Medical Picture Podcast on YouTube:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UCzNUxmYdIU_U8I5hP91Kk7A⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Find Sonal on LinkedIn:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/sonapate/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠And checkout the website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://paintthemedicalpicturepodcast.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠If you'd like to be a sponsor of the Paint The Medical Picture Podcast series, please contact Sonal directly for pricing: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠PaintTheMedicalPicturePodcast@gmail.com⁠

MNF Reactions: 49ers defeat Colts..

This episode explores the multifaceted nature of innovation in orthopedic surgery, from creative problem-solving in clinical practice to collaborating with industry on new device development. Dr. Robert Orfaly hosts a conversation with Dr. Amy Ladd, Chief of Stanford's Chase Hand & Upper Limb Center, a recognized leader in the field whose career includes pioneering research in thumb CMC arthritis, patents, and instrument design. Dr. Amy Ladd shares her perspective on fostering intellectual curiosity early in one's career, the process of turning a simple idea into intellectual property, and the evolving relationship between academic institutions, industry, and orthopedic surgeons. Practical advice is given for trainees, mid-career surgeons, and anyone inspired to pursue innovation, with stories ranging from creating specialized surgical instruments to applying motion analysis technology from upper limb research to optimizing golf swings. The episode also discusses the importance of networking across disciplines and the realities of developing and commercializing new medical devices, emphasizing that creativity and collaboration are central to advancing patient care. Host: Robert Orfaly, MD, MBA, FAAOS, Editor in Chief, AAOS Now  Guest: Amy Ladd, MD, FAAOS, Chief of Stanford's Chase Hand & Upper Limb Center; Chief of the Children's Hand Clinic at Lucile Salter Packard Children's Hospital at Stanfordand; and the Elsbach-Richards Professor of Surgery and Professor, by courtesy, of Medicine (Immunology & Rheumatology) and Surgery (Plastic and Reconstructive Surgery), at Stanford University Medical Center Production and Editing: MK Quinn Media

Biomanufacturing has always dealt with the challenge of turning vast, complex datasets and intricate production steps into life-changing therapies. But when batch records multiply and process deviations loom, how do biotech teams make sense of it all? In this episode, we move beyond theory to the nuts and bolts of how AI - when thoughtfully deployed - can turn bioprocessing chaos into actionable intelligence, paving the way for the factory of the future.Our guest, Ilya Burkov, Global Head of Healthcare and Life Sciences Growth at Nebius AI, doesn't just talk about data wrangling and algorithms—he's spent years building tools and strategies to help scientists organize, contextualize, and leverage real-world datasets. Having worked across tech innovation and pharmaceuticals, Ilya Burkov bridges cutting-edge computation with the practical realities of CMC development and manufacturing, making him a trusted voice on how bioprocessing is rapidly changing.Highlights from the episode:Advice for biotech scientists on learning from innovations in other industries (00:02:21)Tackling the complexities of organizing huge and often unstructured datasets in bioprocessing (03:08)Techniques and tools to structure, label, and prepare data for AI—including Nebius's in-house tool, Tracto AI (06:24)Strategies for startups and small teams—how to begin implementing AI and what areas of bioprocessing to focus on first (10:12)The vision for the “factory of the future”: AI-driven, interconnected, and self-learning manufacturing environments (08:11)Navigating the decision between on-premise and cloud computing for scalable, cost-effective AI workloads (12:32)The importance of partnership between scientists and AI, emphasizing collaboration and data-driven decisions (00:15:47)Wondering how to kick off your own AI-enabled bioprocessing project, or what to insource versus outsource as you scale? This episode gives you a grounded starting point—minus the buzzwords and empty promises.Connect with Ilya Burkov:LinkedIn: www.linkedin.com/in/ilyaburkovContact email: ilya.burkov@nebius.comNebius: www.nebius.comIf this topic grabbed you, you'll love these related episodes focusing on advanced modeling, continuous manufacturing, and Digital TwinsEpisodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe LicariEpisodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisode 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

1:22 - Behind the FTF curtain.4:20 - Nick dealing with more fan venom then ever.13:12 - Silver-lining to the Chiefs season (if any)?17:13 - Time to for Nick to hop on the 49ers / Purdy bandwagon.20:20 - Kyle Shanahan should be in COTY conversations. CMC should get MVP votes.25:20.- Warriors talk27:54 - NBA expansion, which cities have a shot?30:21 - Real beef with Pablo Torre? Yes? No? Something in between?32:00 - Hoosiers34:30 - Grandpa Nick Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube, or visit our website CMChurch.com

Welcome to the Paint The Medical Picture Podcast, created and hosted by Sonal Patel, CPMA, CPC, CMC, ICD-10-CM.Thanks to all of you for making this a Top 15 Medical Billing & Coding Podcast for 5 Years on Feedspot. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sonal's 16th Season starts up and Episode 16 features a Newsworthy update on the PEPPER program. It's back.Sonal's Trusty Tip and compliance recommendations focus on skin substitutes and the upcoming LCDs.Spark inspires us all to reflect on resilience based on the inspirational words of Thomas Edison.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Paint The Medical Picture Podcast now on:Spotify: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/show/6hcJAHHrqNLo9UmKtqRP3X⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple Podcasts: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/paint-the-medical-picture-podcast/id153044217⁠7⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon Music: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://music.amazon.com/podcasts/bc6146d7-3d30-4b73-ae7f-d77d6046fe6a/paint-the-medical-picture-podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Find Paint The Medical Picture Podcast on YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UCzNUxmYdIU_U8I5hP91Kk7A⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Find Sonal on LinkedIn:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/sonapate/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠And checkout the website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://paintthemedicalpicturepodcast.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠If you'd like to be a sponsor of the Paint The Medical Picture Podcast series, please contact Sonal directly for pricing: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠PaintTheMedicalPicturePodcast@gmail.com⁠⁠⁠

Across biotech labs, researchers swim in oceans of process data: sensor streams, run records, engineering logs, and still, crucial decisions get stuck in spreadsheets or scribbled into fading notebooks. The challenge isn't having enough information, it's knowing which actions actually move the needle in cell culture productivity, process stability, and faster timelines.This episode, David Brühlmann brings on Ilya Burkov, Global Head of Healthcare and Life Sciences Growth at Nebius AI. With a career spanning NHS medicine, regenerative research, and cloud infrastructure, Ilya Burkov has lived the leap from microscope to server room. He's seen firsthand how digital twins, autonomous experimentation, and cloud-first strategies are shifting the way biologics are developed and scaled.Topics discussed:Shifting from experimental-based to computational bioprocess development, and the evolving role of human expertise vs. AI (02:48)Ilya Burkov's journey from medicine and orthopedics to AI and cloud infrastructure (04:15)Solving data silos and making real-time decisions with digital twins and automated analytics (06:36)The impact of AI-driven lab automation and robotics on drug discovery timelines (08:51)Using AI to accelerate cell line selection, cloning, and protein sequence optimization (10:12)Why wet lab experimentation is still essential, and how predictive modelling can reduce failure rates (11:15)Reducing costs and accelerating development by leveraging AI in process screening and optimization (12:32)Strategies for smaller companies to effectively store and manage bioprocess data, including practical advice on cloud adoption and security (14:30)Application of AI and digital twins in scale-up processes, and connecting diverse data types like CFD simulations and process data (17:18)The ongoing need for human expertise in interpreting and qualifying data, even as machine learning advances (19:09)Wondering how to stop your own data from gathering dust? This episode unpacks practical strategies for storing and leveraging your experimental records - whether you're in a major pharma or a small startup with limited tech resources.Connect with Ilya Burkov:LinkedIn: www.linkedin.com/in/ilyaburkovContact email: ilya.burkov@nebius.comNebius: www.nebius.comIf this topic grabbed you, you'll love these related episodes focusing on advanced modeling, continuous manufacturing, and Digital TwinsEpisodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe LicariEpisodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisode 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

JMToWin from One Week Season walks us through the Week 15 DFS slate from a GPP perspective, shares his top plays at each position, and then builds a DraftKings lineup using some of his favorite building blocks. In the second half, ShipMyMoney from Run The Sims shares sneaky stacks for Week 15 tournaments and spots with input volatility.

Hall of Fame linebacker Patrick Willis, now an Alumni Ambassador for San Francisco after spending his entire career in the Bay, joins "49ers Talk" host Matt Maiocco to discuss the impact Super Bowl LX can have on the region and how its immersive, family-friendly festivities can be enjoyed by all who attend -- whether they have a ticket or not. Patrick and Matt also tackle the 49ers' surprising run this season and how overcoming adversity has been a hallmark of their success. Willis expands on what San Francisco needs to focus on in its final four games, as well as how his relationship with the organization affords him the opportunity to connect with upcoming great 49ers players. Jennifer Lee Chan also joins Matt to paint the NFC playoff picture, review roster changes and injury updates, plus detail San Francisco's final stretch.--(6:00) Who deserves the most credit for 49ers' 2025 success?(9:00) How 49ers stayed together in their pursuits this season(11:30) Breaking down the NFC playoff picture(17:00) How will the 49ers scheme for No. 1 draft pick QB Cam Ward this week?(23:30) Willis on 49ers' surprising 9-4 record, chances of reaching Super Bowl at home(25:30) Willis on how the 49ers reacted to all injuries this season(27:00) Willis shares advice he gives to young, older 49ers players(31:30) How would Patrick Willis in his prime face CMC?(38:00) 49ers Injury/Roster Updates Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

12-11 Dirty Work Hour 1: Kyle Shanahan joins the show with the latest on the health of CMC and the feel of the team after the latest BYE in 49ers historySee omnystudio.com/listener for privacy information.

What happens when a modular construction company leads with people first? Jon Scott of Creative Modular Construction joins the show to share how their motto—“We build people. We build buildings.”—is more than a slogan; it's the engine behind their remarkable growth. Jon walks through how CMC develops leaders on the shop floor, supports individuals from all backgrounds, and creates a culture where trust, purpose, and personal transformation translate directly into performance. We also discuss how CMC's people-first mindset has made it easier to adopt new processes and technologies (like Strucsoft) as they scale, blending craftsmanship, innovation, and culture into a resilient modular workflow. You'll Learn: How CMC builds a people-first culture that drives productivity and retention • Why investing in personal growth leads to stronger teams and better outcomes • How trust and purpose accelerate technology adoption and process improvements • What culture-building looks like in a fast-paced modular fabrication environment • How CMC is evolving its workflows as it scales its modular operations A powerful episode for anyone interested in modular construction, leadership development, or building high-performing teams through culture. MEET OUR GUEST Jonathan Scott serves as the Lead Draftsman at Creative Modular Construction, where he oversees the design and drafting behind a wide range of modular building projects. With a deep understanding of construction, engineering coordination, and practical field needs, Jonathan is the bridge between imagination and execution—translating concepts into clear, buildable plans that crews can trust. He's passionate about improving processes, solving complex layout challenges, and helping push the modular industry forward through smarter design. Outside of work, Jonathan enjoys life with his family and doing outreach in his community, and brings a grounded, faith-driven perspective to both his personal and professional life. TODD TAKES Building People Builds Performance CMC's commitment to “building people” isn't just a cultural slogan—it's a strategic advantage. When you invest in purpose, stability, and real community, people show up differently. They're engaged, they grow, and the work improves. Culture isn't an add-on for them; it's the engine behind everything they do. Trust Is the Foundation of Tech Adoption Introducing new tools like Strucsoft can be uncomfortable, but CMC's people leaned in because they trust the leadership guiding those decisions. That trust removes friction and accelerates adoption. When your team believes you're making choices that truly help them, change becomes something they embrace—not resist. When Purpose Meets Technology, Growth Takes Off The jump from producing two buildings in three days to three buildings in a single day is incredible. It's what happens when a clear mission, a supportive culture, and the right digital tools align. CMC shows that innovation isn't just about software—it's about creating a system where people and technology elevate each other.   More Resources  Thanks for listening! Please be sure to leave a rating and/or review and follow up our social accounts. Bridging the Gap Website Bridging the Gap LinkedIn Bridging the Gap Instagram Bridging the Gap YouTube Todd's LinkedIn   Thank you to our sponsors! Graitec North America Graitec North America LinkedIn Autodesk's Website   Other Relevant Links: Creative Modular Construction Website  

Its Week 14 in the NFL, and the 49ers finally have reached their bye. As San Francisco players rest and recuperate, "49ers Talk" co-hosts Matt Maiocco and Jennifer Lee Chan take a pulse on the 49ers' season with just four regular-season games left. Jennifer, Matt, and later Greg Papa, discuss if Kyle Shanahan's current coaching staff is his best yet, and if that makes him a strong candidate for his first NFL Coach of the Year award. They also detail the 49ers' latest injuries and roster additions, then discuss if Christian McCaffrey's public support of Roger Craig can convince the Pro Football Hall of Fame committee to induct the legendary 49ers running back.--(2:00) How wind vs. Browns impacted Shanahan's decisions(3:00) 49ers injury updates, possible replacements(11:00) Could Eric Kendricks contribute to 49ers' defense after LB injuries?(15:00) Former 49ers RB Roger Craig announced as one of three finalists in senior category for Pro Football Hall of Fame(17:00) CMC offers public support for Craig's possible induction(24:00) Greg Papa on the 49ers being superbly coached in all three phases this season(28:00) Is this Shanahan's best coaching staff as a whole in his time with the 49ers?(33:00) It wouldn't shock Papa if Kendricks becomes MIKE linebacker to end the season(40:00) Could we possibly see two 49ers RBs enter HOF in the same year? (Gore, Craig) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join Ryan Wormeli and Pat Fitzmaurice as they tackle YOUR questions LIVE on Discord on the 1st Tuesday evening of each month at 5 PM ET at fantasypros.com/chat. The fellas break down some changes to the dynasty trade value chart before diving into your questions in the second half of the show! Timestamps: (May be off due to ads) Intro - 0:00:00 QB Ranking Changes - Drake Maye - 0:03:20 JJ McCarthy - 0:08:45 Reality Sports Online - 0:12:50 RB Ranking Changes - Omarion Hampton, Breece Hall - 0:13:45 WR Ranking Changes - JSN, George Pickens, Christian Watson - 0:18:47 TE Rankings Changes - Loveland, Terrance Ferguson, Isaiah Likely - 0:26:39 FantasyPros Trade Analyzer - 0:31:18 What To Do With Marshawn Lloyd and Jordan Mason - 0:23:26 Is My Roster Ready to Win? - 0:35:18 Loaded at WR, but Struggling at RB - 0:38:52 Rebuilding, but what do I do at QB? - 0:43:50 FantasyPros Discord - 0:49:13 Am I Overpaying for Brock Bowers? - 0:49:43 Sutton + Picks for Darnold and Waddle? - 0:53:25 Picks for CMC & Waddle? - 0:54:30 Which Keeper for 2026? - 0:55:19 Which Value QB Should I Trade Addison For? - 0:56:47 Addison & Two 26 1st's for Justin Jefferson - 0:58:13 When Should Dynasty Trade Deadlines Be? - 1:00:11 Jaylen Warren & Chris Godwin for a 2026 1st? - 1:02:36 Is This The Worst It Gets for Monangi? - 1:02:50 Helpful Links: Reality Sports Online - By now, most of you have probably heard of Reality Sports Online, the powerful Fantasy Sports platform where Owners get to build and manage their Fantasy team like an NFL General Manager. But, the question is, have you tried it? It’s time to go see what all the buzz in the dynasty community is about. If you like what you see, use the promo code "FANTASYPROS" to receive a 10% discount on your team or league today! Fantasy Just Got Real at RealitySportsOnline.com. Dynasty Rookie Draft Simulator - Our Dynasty Rookie Draft Simulator lets you complete a mock in minutes with no waiting between picks! Customize your league settings to match your league’s exact format. Premium subscribers can test trade scenarios by mocking with their traded draft picks. Prepare for rookie drafts AND dynasty startup drafts in one place! Use the Dynasty Rookie Draft Simulator to dominate your rookie draft today at fantasypros.com/simulator! Trade Analyzer - Evaluate trades with confidence using FantasyPros' Trade Analyzer. Instantly see the impact of trades on your team and get expert recommendations. Whether you're making a 2-for-1 deal or swapping a couple draft picks for that stud who will help you win now, the Trade Analyzer will help you optimize your roster and make smarter decisions. Try the Trade Analyzer today at fantasypros.com/myplaybook or on the Fantasy Football My Playbook app and dominate your league! Join us on Discord - Join our FantasyPros Discord Community! Chat with other fans and get access to exclusive AMAs that wind up on our podcast feed. Come get your questions answered and BE ON THE SHOW at fantasypros.com/chatSee omnystudio.com/listener for privacy information.

The 49ers are entrenched in the final NFC playoff spot as they prepare to face the Cleveland Browns. However, with low temperatures, high-winds, and possible perception forecast for Sunday's matchup, holding onto that precious wild card spot might be more complicated. Having lost their previous contest in Cleveland under similar conditions in 2023, San Francisco will be tasked with executing their offense more efficiently this time while mitigating current NFL sack leader Myles Garrett. On this episode of "49ers Talk," co-hosts Matt Maiocco and Jennifer Lee Chan discuss Brock Purdy's regression last week against the Panthers and how he and the 49ers' offense can minimize mistakes against familiar obstacles in inclement weather and a formidable pass-rush. Also, Matt and Jennifer provide injury updates, surprising takes on a San Francisco offensive line playing well under-the-radar and where the 49ers might look in the draft. They also praise the evolution of Christian McCaffrey's game during an incredible individual season.--(4:00) Purdy's attributes as a starter -- anticipation, decisiveness, accuracy - were absent on three INTs(9:00) This is the first time Purdy has dealt with significant in-season time off, and he's adjusting(11:00) Will precipitation ahead of the game in Cleveland play a role in the outcome?(18:00) 49ers Injury Updates (Bethune, Okuayinonu, Piñeiro out)(22:00) Myles Garrett will be a handful for Trent Williams and offensive line(24:00) Matt believes the 49ers' OL starters this year might not change next year given their performance(32:00) CMC leads the league in rushing attempts and receptions, and is San Francisco's MVP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.